Cureus . Transient Anti-Phospholipid Antibodies in Two Patients With COVID-19

[tetano]

Cureus


. 2021 Jan 31;13(1):e13026.
doi: 10.7759/cureus.13026.
Transient Anti-Phospholipid Antibodies in Two Patients With COVID-19


Nino Balanchivadze ¹ , Peter Xie ¹ , Philip Kuriakose ¹ , Bernd Barthel ¹ , Vrushali Dabak ¹



Affiliations

• PMID: 33665050
• PMCID: PMC7924965
• DOI: 10.7759/cureus.13026

Abstract

We report two cases of coronavirus disease 2019 (COVID-19) in patients who developed pulmonary embolism and transient anti-phospholipid antibodies. At the time of presentation with acute pulmonary embolism, both patients had leukocytosis and increased levels of anti-cardiolipin antibodies, which resolved at testing 12 weeks after initial presentation. Studying cases of pulmonary embolism and increased anti-phospholipid antibodies in the context of COVID-19 could be one of the factors for elucidating the possible connection between severe acute respiratory syndrome coronavirus 2 infection, anti-phospholipid antibodies, and thrombosis.

Keywords: anti-phospholipid antibodies; b-cell proliferation; covid-19; venous thromboembolism.